CRDF (Cardiff Oncology) Short Ratio


CRDF Cardiff Oncology Inc CRDF
48 GF Score
Price $1.33
GF Value $1.41
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CRDF
48GF Score
Cardiff Oncology Inc CRDF
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $1.33 is trading 6% below its estimated GF Value™ of $1.41. GuruFocus considers Cardiff Oncology to be Fairly Valued.

Key valuation signals for CRDF:

  • Short Ratio:
  • GF Value™: $1.41 vs. price of $1.33 (6% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
48GF Score

Get the complete analysis for CRDF

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price
$1.41
GF Value